Compare · PETQ vs SCNX
PETQ vs SCNX
Side-by-side comparison of PetIQ Inc. (PETQ) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PETQ and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- PETQ is the larger of the two at $570.2M, about 39.9x SCNX ($14.3M).
- SCNX has hit the wire 5 times in the past 4 weeks while PETQ has been quiet.
- PETQ has more recent analyst coverage (8 ratings vs 0 for SCNX).
- Company
- PetIQ Inc.
- Scienture Holdings Inc.
- Price
- $30.99+0.02%
- $0.36-1.96%
- Market cap
- $570.2M
- $14.3M
- 1M return
- -
- -16.19%
- 1Y return
- -
- -66.33%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 5
- Recent ratings
- 8
- 0
PetIQ Inc.
PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Latest PETQ
- PetIQ Names Camillo Pane as Chief Executive Officer
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- SEC Form 15-12G filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, GENERAL COUNSEL Carter William J. returned 3,497 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest SCNX
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Scienture Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits